INCMOR0208-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINA
| abstract |
Doppel-blind, Placebo-kontrollierte, randomisierte Phase 3 Studie zur Evaluation eines zusätzlichen klinischen Benefits durch die Zugabe des CD19-Antikörpers Tafasitamab zu Rituximab-Lenalidomid bei Patienten mit rezidiviertem/refraktärem Follikulären Lymphom Grad 1-3a oder Marginalzonenlymphom |
| project partner | Syneos Health, Incyte |
| type of project | clinical studies |
| status | ongoing - recruiting phase |
| start of project | 2022 |
| end of project | 2023 |
| study design | Phase III |
| responsible person | Dr. med. Martin Fehr |